Why BioAge Labs’ promising obesity drug trial of azelaprag came to an abrupt halt

BioAge Labs, a clinical-stage biopharmaceutical company focused on metabolic disease research, has announced the discontinuation of its STRIDES Phase 2 obesity drug trial. The decision ... Read More